In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Phil Greenfield

Latest From Phil Greenfield

UK Competition Watchdog Has Concerns About Stryker/Wright Medical Merger

The UK Competition and Markets Authority has concerns over the impact on the market for ankle replacements that would result from Stryker's planned $4bn acquisition of Wright Medical.

United Kingdom Commercial

FDA Pulls Chembio’s Rapid Test As Purge Of ‘Inaccurate’ Antibody Tests Continues

Chembio’s stock opened down 60% the day after the FDA’s decision to revoke its EUA for the first US rapid test for antibodies to SARS-CoV-2.

United States Coronavirus COVID-19

Antibody Testing During And After The Pandemic: Not All Tests Are Created Equal

While the main role of SARS-CoV-2 antibody testing is currently limited to determining exposure to the virus in populations, the scientific community is working hard to define the neutralizing properties of the antibodies detected, and the duration of the immune response. As a result, antibody testing could be here to stay for the long term for monitoring populations, testing vaccines and selecting patients for trials of a variety of new therapies to treat numerous conditions.

Research & Development Clinical Trials

Siemens Healthineers Adds Muscle To Global Antibody Testing Effort, In Talks With Vaccine Developers

The company now has US emergency use designation for its new SARS-CoV-2 test, which can run on its global installed base of 20,000 analyzers at a current capacity of 50 million tests per month.

Coronavirus COVID-19 Regulation

Japan Approves Country’s First SARS-CoV-2 Antigen Test Kit As It Aims To Ramp Up Testing Numbers

The test, made by Fujirebio, will help Japan to reach its 400,000-per-week COVID-19 test target.

Japan Coronavirus COVID-19

FDA Grants EUA For Roche’s Coronavirus Antibody Test

The company says the serology test has a specificity of 99.8% and sensitivity of 100%

Research & Development Regulation
See All
UsernamePublicRestriction

Register